Drugs Containing Excipient (Inactive Ingredient) CARBOMER HOMOPOLYMER TYPE B/C

« Back to Dashboard

Generic drugs containing CARBOMER HOMOPOLYMER TYPE B/C excipient

Company	Ingredient	NDC	Excipient
Physicians Total Care Inc	permethrin	54868-5391	CARBOMER HOMOPOLYMER TYPE B/C

Carbomer Homopolymer Type B/C Market Dynamics, Patent Position, Suppliers, and Financial Outlook

Last updated: September 5, 2026

Carbomer homopolymer Type B/C is a pharmaceutical-grade crosslinked polyacrylic acid excipient used as a viscosity modifier, suspending agent, bioadhesive, rheology controller, and gel-forming polymer. Demand is tied to topical, ophthalmic, oral, rectal, vaginal, and selected controlled-release dosage forms.

The market is fragmented by grade and application rather than dominated by a single global product category. Lubrizol has the strongest branded position through the Carbopol portfolio, while Chinese and regional manufacturers compete on price, local regulatory registration, and supply continuity. Public companies do not separately disclose revenue for Carbomer Homopolymer Type B/C, so financial analysis must use supplier segment data, pharmaceutical formulation activity, regional capacity, and grade-level pricing indicators.

What is Carbomer Homopolymer Type B/C?

Carbomer Homopolymer Type B/C is a high-molecular-weight, crosslinked polymer of acrylic acid. It is normally supplied as a dry, white, hygroscopic powder that swells and develops viscosity after dispersion and neutralization.

The polymer is used at low concentrations, often below 2% of a finished formulation. Its commercial value comes from functional performance rather than volume consumption. Small changes in polymer grade, particle size, neutralization, electrolyte tolerance, and rheological profile can affect product quality.

What are the principal pharmaceutical functions?

Function	Typical pharmaceutical application
Viscosity modification	Topical creams, gels, lotions and oral liquids
Suspension stabilization	Oral suspensions and dermatological products
Bioadhesion	Buccal, vaginal, rectal and ophthalmic formulations
Controlled release	Matrix tablets, ocular delivery and mucoadhesive systems
Gel formation	Topical, ophthalmic and mucosal dosage forms
Emulsion stabilization	Creams and multiphase dermatological products

Carbomer is generally neutralized with bases such as sodium hydroxide, potassium hydroxide, tromethamine or aminomethyl propanol. The neutralized polymer expands and produces a high-viscosity gel.

Type B and Type C designations are compendial or supplier-grade classifications. They should not be treated as interchangeable with branded grades without formulation and regulatory comparability testing. The relevant specification includes viscosity, loss on drying, residual solvents, heavy metals or elemental impurities, polymer identification and microbial quality.

Which pharmaceutical products use Carbomer Homopolymer Type B/C?

The largest demand pool is topical and mucosal formulation development. Carbomer is also used in products where a stable suspension or bioadhesive matrix is required.

Common dosage forms

• Dermatological gels and creams
• Ophthalmic gels and lubricating products
• Oral suspensions
• Buccal and sublingual systems
• Vaginal and rectal gels
• Transdermal and topical delivery systems
• Controlled-release tablets
• Nasal and mucosal preparations
• Veterinary pharmaceutical gels

The excipient is particularly attractive where formulators need high viscosity at low use levels. This reduces the mass of excipient required compared with some cellulose derivatives, although the final performance depends on pH, ionic strength, active pharmaceutical ingredient compatibility and manufacturing shear.

Which grades compete with Type B/C?

Competitive materials include:

• Carbomer homopolymer grades
• Carbomer copolymers
• Acrylates/C10-30 alkyl acrylate crosspolymers
• Hydroxypropyl methylcellulose
• Hydroxyethyl cellulose
• Sodium carboxymethylcellulose
• Poloxamers
• Xanthan gum
• Polycarbophil
• Sodium alginate

Carbomer competes most directly with cellulose polymers and polycarbophil in gels, suspensions and mucoadhesive systems. The substitution risk is lower after a product has been approved because changing the rheology modifier can trigger reformulation, stability work, process validation and regulatory review.

How large is the Carbomer Homopolymer Type B/C market?

No public market database separately reports global sales for Carbomer Homopolymer Type B/C. Published market studies generally combine cosmetic, industrial, pharmaceutical and personal-care carbomers. Their estimates therefore cannot be used as audited pharmaceutical Type B/C revenue.

The addressable market is driven by five factors:

1. Growth in topical generic medicines.
2. Expansion of ophthalmic and mucosal drug delivery.
3. Increased use of semisolid dosage forms in emerging markets.
4. Pharmaceutical outsourcing and contract development activity.
5. Substitution away from solvent-heavy or less stable gel systems.

Pharmaceutical demand is smaller by volume than cosmetics and personal care, but it has higher unit value and more persistent customer relationships. Pharmaceutical grades require tighter documentation, validated manufacturing, traceability, change-control discipline and regulatory support.

What is the pricing structure?

Pricing varies according to:

• Pharmacopeial compliance
• Grade and viscosity
• Batch size
• Packaging configuration
• Country of manufacture
• Regulatory documentation
• Qualification status
• Supply agreement duration
• Demand for a specific branded grade

Commodity or non-pharmaceutical carbomer is generally more exposed to price competition. Pharmaceutical-grade material commands a premium because switching suppliers can require technical qualification and regulatory assessment.

Who are the leading Carbomer Homopolymer Type B/C suppliers?

Lubrizol

Lubrizol is the leading branded supplier through its Carbopol pharmaceutical portfolio. Relevant pharmaceutical products include Carbopol 971P NF, Carbopol 974P NF and Carbopol 980 NF, subject to market-specific availability and regulatory status. The company positions these grades for oral, topical, ophthalmic and mucosal applications (Lubrizol, 2024a).

Lubrizol’s competitive strengths include:

• Long-standing pharmaceutical-grade brand recognition
• Technical formulation support
• Global documentation
• Established customer qualification
• Broad grade portfolio
• Strong presence in personal care and pharmaceutical formulation

Its risk is price competition from Asian suppliers and the possibility that customers qualify multiple sources for supply security.

Ashland

Ashland supplies pharmaceutical excipients and specialty ingredients, including polymers used in oral, topical and controlled-release formulations. Its pharmaceutical portfolio is more diversified across cellulose derivatives, film coatings and other excipients than a single carbomer franchise (Ashland, 2024).

Ashland competes through formulation support, regulatory infrastructure and cross-selling across excipient categories.

Chinese and regional producers

Chinese manufacturers have increased competition in carbomer and related acrylic polymer grades. Their advantages include lower production costs, expanding domestic pharmaceutical demand and improved export capability. Their disadvantages can include lower brand recognition, inconsistent documentation across suppliers and longer qualification cycles at multinational pharmaceutical companies.

Regional suppliers can win business where customers prioritize dual sourcing, local content, shorter lead times or cost reduction.

What drives demand for Carbomer Homopolymer Type B/C?

Topical generic medicines

Topical generics use carbomer in gels, creams and suspensions. Growth in dermatology, pain management, antifungal therapy and anti-inflammatory products supports demand.

Carbomer is also used in over-the-counter products, but pharmaceutical grades benefit from stricter quality requirements and established formulation histories.

Ophthalmic drug delivery

Ophthalmic gels require viscosity control, clarity, sterility compatibility and acceptable ocular comfort. Carbomer can extend residence time on the ocular surface and reduce dosing frequency in some formulations.

This application has attractive technical value but high qualification barriers. Sterility, endotoxin, particulate, container-closure and extractables requirements increase development complexity.

Mucosal and bioadhesive delivery

Carbomer’s mucoadhesive properties support vaginal, buccal, rectal and nasal products. The category remains formulation-sensitive because polymer concentration and neutralization affect drug release, adhesion and patient acceptability.

Emerging-market pharmaceutical manufacturing

India, China, Brazil, Southeast Asia and the Middle East have expanding generic and contract manufacturing bases. Their growth supports demand for excipients that are available in pharmacopeial grades and compatible with standard high-shear manufacturing equipment.

What regulatory status applies to Carbomer Homopolymer Type B/C?

Carbomer is an excipient, not an independently approved active pharmaceutical ingredient. Its regulatory status depends on the finished drug product and the grade used in that product.

United States

The U.S. Food and Drug Administration’s Inactive Ingredient Database records excipient use by route, dosage form and maximum potency. A listed use does not create a universal approval for every carbomer grade or every formulation (FDA, 2024).

Sponsors must establish that the selected grade is suitable for the intended route and concentration. A change between grades can require justification based on equivalence, impurity profile, viscosity and functional performance.

Carbomer products used in approved drugs may also appear in product labeling, abbreviated new drug applications, new drug applications or master-file documentation. The excipient itself does not receive Orange Book exclusivity.

Europe

European regulatory review focuses on excipient quality, safety, control strategy and suitability for the route of administration. The European Medicines Agency’s excipient guidance requires applicants to provide relevant quality and safety information in the marketing authorization dossier (EMA, 2016).

Pharmacopeial compliance

Relevant standards may include:

• USP-NF
• European Pharmacopoeia
• British Pharmacopoeia
• Japanese Pharmacopoeia
• Chinese Pharmacopoeia

A supplier’s statement that a product is “pharmaceutical grade” does not establish compliance with every applicable monograph. Buyers must review the current certificate of analysis, change-control procedures and compendial claim.

What patents protect Carbomer Homopolymer Type B/C?

Carbomer itself is a mature polymer technology. Core composition-of-matter patents for conventional crosslinked polyacrylic acid polymers are generally expired or commercially irrelevant. The principal intellectual-property risks are not basic carbomer ownership.

Where does current patent value reside?

Current patent activity may involve:

• Specific pharmaceutical formulations
• Drug-carbomer combinations
• Controlled-release dosage forms
• Ophthalmic delivery systems
• Mucoadhesive formulations
• Manufacturing processes
• Particle-size distributions
• Crosslinking conditions
• Neutralization systems
• Low-irritation or improved-spreadability formulations
• Combination products and delivery devices

A patent claiming “a formulation comprising carbomer” may be narrow if it requires a defined active ingredient, concentration, pH, viscosity range, release profile or manufacturing step.

Does Carbomer have Orange Book-listed patents?

Carbomer excipients do not ordinarily have their own Orange Book listings. Orange Book patents are listed against approved drug products, not against excipients as standalone commercial materials.

A finished drug containing Carbomer Homopolymer Type B/C may have listed formulation or method-of-use patents. Any Paragraph IV risk therefore relates to the drug product and its listed patents, not to carbomer supply as an excipient.

When does Carbomer Homopolymer Type B/C lose exclusivity?

The excipient has no single market-wide exclusivity date. Conventional carbomer technology is already broadly available from multiple suppliers. Exclusivity is created through:

• Supplier trademarks
• Proprietary grades
• Manufacturing know-how
• Customer qualification
• Regulatory documentation
• Formulation patents
• Contractual supply arrangements

A branded grade can retain commercial differentiation after core polymer patents expire because pharmaceutical customers value consistency and validated performance.

What are the barriers to supplier substitution?

Barrier	Commercial effect
Formulation requalification	Extends switching timelines
Regulatory assessment	May require post-approval documentation
Viscosity differences	Can alter manufacturing and dosing performance
Impurity differences	May affect safety or stability review
Particle-size variation	Can affect dispersion and hydration
Customer audit requirements	Favors established suppliers
Supply-chain qualification	Limits rapid sourcing changes

How strong is the patent and commercial position?

The patent position for the underlying excipient is weak to moderate because the basic technology is mature and multiple suppliers exist. The commercial position of established pharmaceutical-grade suppliers is stronger than the patent position.

Strength assessment

Factor	Assessment
Basic composition patents	Low strategic protection
Grade-specific know-how	Moderate
Regulatory documentation	Moderate to strong
Customer qualification	Strong once approved
Brand recognition	Strong for established suppliers
Manufacturing barriers	Moderate
Switching costs	Moderate to strong
Formulation-level patents	Highly variable
Generic substitution risk	Moderate
Supply disruption risk	Supplier-dependent

The strongest moat is cumulative: consistent batches, regulatory history, technical service, global supply and customer-specific formulation knowledge.

What is the financial trajectory for Carbomer Homopolymer Type B/C?

The financial trajectory is likely to be positive in nominal terms but uneven by supplier and geography.

Base-case outlook

The base case has:

• Low- to mid-single-digit annual volume growth in pharmaceutical applications
• Higher growth in ophthalmic, mucosal and topical delivery niches
• Stable or declining real pricing for standardized grades
• Premium pricing for qualified, documented and supply-secure grades
• Margin pressure from Asian capacity and customer dual sourcing
• Higher value capture in technical service and formulation support

Revenue growth is more likely to come from volume expansion, new customer qualification and mix improvement than from broad price increases.

Bull-case conditions

A stronger trajectory would require:

• Increased topical generic launches
• More ophthalmic gel products
• Greater use of bioadhesive delivery systems
• Regulatory acceptance of additional regional suppliers
• Capacity constraints at incumbent producers
• Successful premiumization of high-purity and low-irritation grades

Bear-case conditions

Downside risks include:

• Substitution by cellulose polymers or polycarbophil
• Customer reformulation to reduce excipient cost
• Weak generic-drug pricing
• Excess capacity in China
• Raw-material cost inflation
• Regulatory findings involving impurities or inconsistent batches
• Reduced use of semisolid dosage forms in favor of solid or liquid products

How does Carbomer compare with competing pharmaceutical excipients?

Attribute	Carbomer	HPMC	CMC	Xanthan gum	Polycarbophil
Viscosity efficiency	High	Moderate to high	Moderate	High	High
Typical gel clarity	High in suitable systems	Variable	Variable	Lower	High
Mucoadhesion	High	Moderate	Moderate	Moderate	High
Electrolyte sensitivity	Can be significant	Moderate	Moderate	Often lower	Can be significant
Topical use	Strong	Strong	Strong	Moderate	Moderate
Ophthalmic use	Strong for selected grades	Strong	Selected use	Limited	Selected use
Cost pressure	Moderate	Moderate	High	High	Moderate
Qualification burden	Moderate to high	High	Moderate	Moderate	High

Carbomer has an advantage in high-viscosity, clear-gel applications. HPMC is often preferred where film formation, controlled release or broader process tolerance is more important. Polycarbophil competes directly in bioadhesive and extended-residence applications.

What generic entry risks affect Carbomer-containing products?

Generic entry risk depends on the finished drug, not the presence of carbomer alone. A generic applicant may use a different carbomer grade if it can demonstrate pharmaceutical equivalence, bioequivalence where required, comparable performance and acceptable product quality.

Key generic risks

• Non-infringement of formulation patents
• Invalidity of narrow viscosity or pH claims
• Substitution of an alternative carbomer grade
• Use of a different polymer with equivalent function
• Paragraph IV challenges to formulation or method patents
• Lack of patent protection for the excipient itself

For topical and locally acting products, formulation sameness and comparative performance can be difficult. That can protect the reference product commercially even where the excipient has no independent patent protection.

What litigation and settlement issues are relevant?

There is no single patent litigation docket for Carbomer Homopolymer Type B/C. Litigation generally arises from finished pharmaceutical products containing carbomer, particularly topical, ophthalmic and controlled-release products.

Relevant disputes may concern:

• Formulation patents
• Viscosity ranges
• Polymer concentration
• Drug-release profiles
• Manufacturing steps
• Bioadhesive claims
• Equivalence of generic products
• Trade secrets involving grade manufacture
• Trademark misuse involving branded carbomer

Settlement agreements in drug litigation may delay generic entry while permitting an authorized generic or license. The commercial terms are usually tied to the finished drug and patent estate rather than the excipient supplier.

What geographic markets offer the strongest growth?

North America

North America remains attractive because of high pharmaceutical-grade standards, established generic manufacturing and demand for complex topical and ophthalmic products. Growth is constrained by buyer consolidation and pricing pressure.

Europe

Europe has strong regulatory discipline and a broad base of generic and specialty pharmaceutical manufacturers. Demand is stable, but procurement often emphasizes dual sourcing and cost control.

China

China is both a production base and a major demand market. Domestic pharmaceutical growth and export capacity support regional suppliers. Price competition is intense.

India

India is a major generic-drug manufacturing center and a significant demand market for excipients. Supplier qualification, documentation and consistency are central purchasing criteria.

Latin America and Southeast Asia

These regions offer growth through local generic manufacturing and imported pharmaceutical products. Distribution infrastructure and regulatory registration can be more important than brand recognition.

Key Takeaways

• Carbomer Homopolymer Type B/C is a mature but commercially important pharmaceutical excipient.
• The strongest applications are topical, ophthalmic, mucosal, bioadhesive and controlled-release formulations.
• Lubrizol has the strongest branded position, while Asian manufacturers increase price and supply competition.
• The basic carbomer technology has limited current patent protection.
• Commercial protection comes from grade consistency, regulatory documentation, customer qualification and formulation know-how.
• Carbomer has no standalone Orange Book exclusivity. Patent risk attaches to finished drug products.
• Pharmaceutical demand should grow faster than commodity carbomer demand, but pricing will remain competitive.
• The most attractive financial opportunities are premium pharmaceutical grades, dual-source qualification, ophthalmic delivery and technical formulation support.
• Revenue and margin data for Type B/C are not separately disclosed by major suppliers, so any precise standalone market-size forecast would be unreliable.

FAQs About Carbomer Homopolymer Type B/C

Is Carbomer Homopolymer Type B/C safe in pharmaceutical products?

Safety depends on the route, concentration, grade, impurity profile and finished formulation. Approved use requires evaluation in the relevant drug-product regulatory dossier.

Can Carbomer Homopolymer Type B/C be replaced without regulatory approval?

A supplier or grade change may require regulatory assessment and supporting comparability data. The required filing depends on the product, jurisdiction and material change.

Is Carbomer Homopolymer Type B/C a biologic excipient?

No. Carbomer is a synthetic polymer excipient and is not a biologic, biosimilar or active pharmaceutical ingredient.

Does Carbomer Homopolymer Type B/C have a patent term?

The underlying polymer technology is mature. Current patents generally concern specific formulations, delivery systems, manufacturing methods or drug combinations rather than the basic excipient.

Which products are most exposed to carbomer supply disruption?

Products using a single qualified supplier, a proprietary grade, an ophthalmic-grade material or a narrow viscosity specification have higher substitution and supply-chain exposure.

References

1. Ashland. (2024). Pharmaceutical excipients and formulation solutions. Ashland Global Holdings Inc.

2. European Medicines Agency. (2016). Guideline on excipients in the dossier for application for marketing authorisation of a medicinal product. EMA.

3. U.S. Food and Drug Administration. (2024). Inactive Ingredient Database. U.S. Department of Health and Human Services.

4. Lubrizol Life Science. (2024a). Carbopol polymers for pharmaceutical applications. Lubrizol Corporation.

5. United States Pharmacopeia. (2024). United States Pharmacopeia and National Formulary. U.S. Pharmacopeial Convention.